THERAVANCE BIOPHARMA, INC. TBPH Income Statement

Theravance biopharma, inc. (TBPH)

Income statement / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13
Revenue:
Revenue
19,862	29,499	12,427	26,150	5,338	15,737	12,838	23,476	8,319	4,515	4,275	3,509	3,087	5,692	19,075	5,471	18,410	3,893	10,698	7,134	20,401	1,433	6,336	2,974	945	175	24	5	22
Costs and expenses:
Cost of goods sold
-	-	-	-	-	632	705	-1,448	826	3,116	985	1,364	565	1,146	332	638	778	3,200	581	505	371	3,222	369	279	188	0	0	0	0
Research and development
66,013	67,025	52,006	46,399	53,818	52,269	52,693	48,621	47,765	51,052	39,343	42,927	40,565	42,014	31,951	32,069	35,678	32,402	30,367	30,377	36,019	42,192	38,324	46,283	41,723	32,470	32,301	30,400	25,408
Selling, general and administrative
26,325	33,046	25,622	22,227	25,186	25,457	21,890	25,007	24,704	29,523	20,944	24,339	20,786	20,366	20,286	20,261	23,596	24,065	22,845	21,545	21,748	21,772	17,705	13,118	19,052	11,785	8,801	8,557	6,788
Total costs and expenses
92,338	100,071	77,628	68,626	79,004	78,358	75,288	72,180	73,295	83,691	61,272	68,630	61,916	63,526	52,569	52,968	60,052	59,667	53,793	52,427	58,138	67,186	56,398	59,680	60,963	44,255	41,102	38,957	32,196
Loss from operations
-72,476	-70,572	-65,201	-42,476	-73,666	-62,621	-62,450	-48,704	-64,976	-79,176	-56,997	-65,121	-58,829	-57,834	-33,494	-47,497	-41,642	-55,774	-43,095	-45,293	-37,737	-65,753	-50,062	-56,706	-60,018	-	-41,078	-38,952	-
Income from investment in TRC, LLC
13,515	11,913	7,197	8,366	6,229	5,428	3,119	1,949	686	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest expense
9,941	8,035	8,068	7,901	7,858	4,071	2,137	2,137	2,137	2,137	2,136	2,137	2,137	1,404	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Loss on extinguishment of debt
-15,464	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other-than-temporary impairment loss
-	-	-	-	-	-	-	-	-	-	8,000	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest and other income, net
1,460	1,137	2,089	2,374	2,795	7,822	1,376	1,284	1,484	1,210	1,124	1,425	1,030	474	344	308	186	112	104	204	211	983	668	214	0	-	0	0	-
Loss before income taxes
-82,906	-65,557	-63,983	-39,637	-72,500	-53,442	-60,092	-47,608	-64,943	-79,933	-66,009	-65,833	-59,936	-58,764	-33,150	-47,189	-41,456	-55,662	-42,991	-45,089	-37,526	-64,770	-49,394	-56,492	-60,018	-	-41,078	-38,952	-
Provision for income tax expense
100	71	-5,552	201	80	-3,295	-659	-6,790	144	6,995	868	454	5,383	8,568	812	36	694	-10,834	4,323	2,514	4,948	-460	5,101	1,723	0	-	0	0	-
Net loss
-83,053	-65,606	-58,431	-39,838	-72,580	-50,186	-59,433	-40,818	-65,087	-86,922	-66,877	-66,287	-65,319	-67,332	-33,962	-47,225	-42,150	-44,828	-47,314	-47,603	-42,474	-64,310	-54,495	-58,215	-60,018	-44,080	-41,078	-38,952	-32,174
Net unrealized gain on available-for-sale investments
367	-	-35	165	130	-	194	329	-120	-	-44	24	-19	-	-142	55	196	-	19	-7	113	-	-97	-	-	-	-	-	-
Total comprehensive loss
-82,686	-	-58,466	-39,673	-72,450	-	-59,239	-40,489	-65,207	-	-66,921	-66,263	-65,338	-	-34,104	-47,170	-41,954	-	-47,295	-47,610	-42,361	-	-54,592	-	-	-	-	-	-32,174
Net loss per share:
Basic and diluted net loss per share (in dollars per share)
-1.40	-1.16	-1.05	-0.72	-1.32	-0.91	-1.10	-0.76	-1.22	-1.64	-1.27	-1.27	-1.27	-1.37	-0.73	-1.06	-1.10	-1.23	-1.40	-1.42	-1.29	-2.02	-1.72	-1.83	-1.89	-	-1.29	-1.23	-
Shares used to compute basic and diluted net loss per share (in shares)
59,463	56,115	55,858	55,529	54,938	54,573	54,248	53,799	53,256	52,925	52,611	52,255	51,617	49,641	46,470	44,407	38,326	36,549	33,689	33,532	32,830	31,757	31,754	31,768	31,741	-	31,741	31,768	-
Share-based compensation expense
15,276	23,913	13,019	11,298	12,220	11,714	11,746	13,855	13,998	17,793	10,685	10,398	10,269	10,040	9,895	9,904	11,330	11,511	12,251	14,662	15,626	-	9,350	-	-	-	-	-	-
Product sales
Revenue
-	-	-	-	-	2,415	3,849	5,361	3,679	4,124	4,140	3,474	3,050	5,032	3,901	5,359	3,311	3,692	2,312	2,124	1,280	1,309	1,303	861	945	0	0	0	0
Collaborative revenue
Revenue
6,632	9,426	8,836	7,650	5,338	10,047	8,989	18,115	4,640	391	135	35	37	660	15,174	112	15,099	201	8,386	5,010	19,121	124	5,033	2,113	0	175	24	5	22
Licensing revenue
Revenue
1,500	-	-	18,500	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Mylan collaboration agreement
Revenue
11,730	-	3,591	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Research and development
Share-based compensation expense
7,865	10,616	6,458	5,720	6,159	5,806	6,294	6,904	6,559	7,668	5,005	4,917	5,101	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Selling, general and administrative
Share-based compensation expense
7,411	13,297	6,561	5,578	6,061	5,908	5,452	6,951	7,439	10,125	5,680	5,481	5,168	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-